Patents by Inventor Yong-Li Zhong

Yong-Li Zhong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL SYNTHETIC PATHWAY TO BELZUTIFAN
    Publication number: 20240010613
    Abstract: The disclosure provides a novel process and synthetic intermediates for making belzutifan, a HIF-2a inhibitor, useful for the treatment of certain VHL-related indications and cancer.
    Type: Application
    Filed: July 3, 2023
    Publication date: January 11, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Daniel A. DiRocco, Jackson Kenai Blender Cahn, Wai Ling Cheung-Lee, Stephanie W. Chun, J. Caleb Hethcox, Heather Claire Johnson, Jungchul Kim, Joshua N. Kolev, Birgit Kosjek, Diane Le, Scott D. McCann, John McIntosh, Jonathan P. McMullen, Jeffrey C. Moore, William Morris, Juan Esteban Velasquez Velez, Matthew S. Winston, Victoria Zhang, Yong-Li Zhong
  • Process for making beta 3 agonists and intermediates
    Patent number: 11767292
    Abstract: The present invention is directed to a process for preparing a compound of formula I-11 through multiple-step reactions:
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: September 26, 2023
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John Y. L. Chung, Kevin Campos, Edward Cleator, Robert F. Dunn, Andrew Gibson, R. Scott Hoerrner, Stephen Keen, Dave Lieberman, Zhuqing Liu, Joseph Lynch, Kevin M. Maloney, Feng Xu, Nobuyoshi Yasuda, Naoki Yoshikawa, Yong-Li Zhong
  • Process for making beta 3 agonists and intermediates
    Patent number: 11708371
    Abstract: The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: July 25, 2023
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John Y. L. Chung, Kevin Campos, Edward Cleator, Robert F. Dunn, Andrew Gibson, R. Scott Hoerrner, Stephen Keen, Dave Lieberman, Zhuqing Liu, Joseph Lynch, Kevin M. Maloney, Feng Xu, Nobuyoshi Yasuda, Naoki Yoshikawa, Yong-Li Zhong
  • PROCESS FOR MAKING BETA 3 AGONISTS AND INTERMEDIATES
    Publication number: 20220073459
    Abstract: The present invention is directed to a process for preparing a compound of formula I-11 through multiple-step reactions:
    Type: Application
    Filed: September 17, 2021
    Publication date: March 10, 2022
    Inventors: John Y.L. CHUNG, Kevin CAMPOS, Edward CLEATOR, Robert F. DUNN, Andrew GIBSON, R. Scott HOERRNER, Stephen KEEN, Dave LIEBERMAN, Zhuqing LIU, Joseph LYNCH, Kevin M. MALONEY, Feng XU, Nobuyoshi YASUDA, Naoki YOSHIKAWA, Yong-Li ZHONG
  • Process for making beta 3 agonists and intermediates
    Patent number: 11124478
    Abstract: The present invention is directed to a process for preparing a compound of formula I-11 through multiple-step reactions:
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: September 21, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John Y. L. Chung, Kevin Campos, Edward Cleator, Robert F. Dunn, Andrew Gibson, R. Scott Hoerrner, Stephen Keen, Dave Lieberman, Zhuqing Liu, Joseph Lynch, Kevin M. Maloney, Feng Xu, Nobuyoshi Yasuda, Naoki Yoshikawa, Yong-Li Zhong
  • Process for Making Beta 3 Agonists and Intermediates
    Publication number: 20210221815
    Abstract: The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.
    Type: Application
    Filed: January 22, 2021
    Publication date: July 22, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: John Y.L. CHUNG, Kevin CAMPOS, Edward CLEATOR, Robert F. DUNN, Andrew GIBSON, R. Scott HOERRNER, Stephen KEEN, Dave LIEBERMAN, Zhuqing LIU, Joseph LYNCH, Kevin M. MALONEY, Feng XU, Nobuyoshi YASUDA, Naoki YOSHIKAWA, Yong-Li ZHONG
  • Process for making beta 3 agonists and intermediates
    Patent number: 10899771
    Abstract: The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.
    Type: Grant
    Filed: October 1, 2019
    Date of Patent: January 26, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John Y. L. Chung, Kevin Campos, Edward Cleator, Robert F. Dunn, Andrew Gibson, R. Scott Hoerrner, Stephen Keen, Dave Lieberman, Zhuqing Liu, Joseph Lynch, Kevin M. Maloney, Feng Xu, Nobuyoshi Yasuda, Naoki Yoshikawa, Yong-Li Zhong
  • Process for Making Beta 3 Agonists and Intermediates
    Publication number: 20200290962
    Abstract: The present invention is directed to a process for preparing a compound of formula I-11 through multiple-step reactions:
    Type: Application
    Filed: February 20, 2020
    Publication date: September 17, 2020
    Inventors: John Y.L. CHUNG, Kevin CAMPOS, Edward CLEATOR, Robert F. DUNN, Andrew GIBSON, R. Scott HOERRNER, Stephen KEEN, Dave LIEBERMAN, Zhuqing LIU, Joseph LYNCH, Kevin M. MALONEY, Feng XU, Nobuyoshi YASUDA, Naoki YOSHIKAWA, Yong-Li ZHONG
  • Process for making beta 3 agonists and intermediates
    Patent number: 10577316
    Abstract: The present invention is directed to a process for preparing a compound of formula I-11 through multiple-step reactions:
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: March 3, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John Y. L. Chung, Kevin Campos, Edward Cleator, Robert F. Dunn, Andrew Gibson, R Scott Hoerrner, Stephen Keen, Dave Lieberman, Zhuqing Liu, Joseph Lynch, Kevin M. Maloney, Feng Xu, Nobuyoshi Yasuda, Naoki Yoshikawa, Yong-Li Zhong
  • Process for Making Beta 3 Agonists and Intermediates
    Publication number: 20200031838
    Abstract: The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.
    Type: Application
    Filed: October 1, 2019
    Publication date: January 30, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: John Y.L. CHUNG, Kevin CAMPOS, Edward CLEATOR, Robert F. DUNN, Andrew GIBSON, R. Scott HOERRNER, Stephen KEEN, Dave LIEBERMAN, Zhuqing LIU, Joseph LYNCH, Kevin M. MALONEY, Feng XU, Nobuyoshi YASUDA, Naoki YOSHIKAWA, Yong-Li ZHONG
  • Substituted phosphoramidate compounds and uses thereof
    Patent number: 10526363
    Abstract: The present invention is directed to Compounds of Formula (I) and salts thereof, wherein R1, R2, R3 and R4 are defined above herein. The present invention is also directed to uses of the compounds of Formula (I) to add phosphoramidate groups onto organic alcohols.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: January 7, 2020
    Assignees: Merck Sharp & Dohme Corp., Merck Sharp & Dohme Ltd.
    Inventors: John Simon Edwards, Peter Richard Mullens, Edward Cleator, Bryon L. Simmons, Courtney K. Maguire, Jeremy Peter Scott, Nobuyoshi Yasuda, Yong-Li Zhong, Lisa F. Frey, Peter G. Dormer, Andrew Brunskill, Artis Klapars, Pu Qian, Yi Zhang, Baoqiang Wan, Eric Ashley
  • Process for making beta 3 agonists and intermediates
    Patent number: 10435410
    Abstract: The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: October 8, 2019
    Assignee: MERCK SHARP & DOHME CORPORATION
    Inventors: John Y. L. Chung, Kevin Campos, Edward Cleator, Robert F. Dunn, Andrew Gibson, R. Scott Hoerrner, Stephen Keen, Dave Lieberman, Zhuqing Liu, Joseph Lynch, Kevin M. Maloney, Feng Xu, Nobuyoshi Yasuda, Naoki Yoshikawa, Yong-Li Zhong
  • Process for making nucleoside phosphoramidate compounds
    Patent number: 10251903
    Abstract: The present invention is directed to a process for making Nucleoside Phosphoramidate Compounds of formula (I): which are useful for the treatment and prophylaxis of HCV infection. The present invention is also directed to compounds that are useful as synthetic intermediates for making the compounds of formula (I).
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: April 9, 2019
    Assignees: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals LLC
    Inventors: Bryon L. Simmons, Kevin R. Campos, Artis Klapars, Alistair J. Stewart, Benjamin A. Mayes, Peter E. Maligres, Alan Hyde, Steven Mark Silverman, Yong-Li Zhong, Adel M. Moussa, Kenneth Baker, Kara Van Valkenburg
  • PROCESS FOR MAKING BETA 3 AGONISTS AND INTERMEDIATES
    Publication number: 20190016729
    Abstract: The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.
    Type: Application
    Filed: September 17, 2018
    Publication date: January 17, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: John Y.L. Chung, Kevin Campos, Edwards Cleator, Robert F. Dunn, Andrew Gibson, R. Scott Hoerrner, Stephen Keen, Dave Lieberman, Zhuqing Liu, Joseph Lynch, Kevin M. Maloney, Feng Xu, Nobuyoshi Yasuda, Naoki Yoshikawa, Yong-Li Zhong
  • Intermediates for preparing CGRP receptor antagonists
    Patent number: 10106541
    Abstract: The invention encompasses a novel process for making piperidinone carboxamide indane and azainane derivatives, which are CGRP receptor antagonists useful for the treatment of migraine.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: October 23, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Frank Chen, Carmela Molinaro, W. Peter Wuelfing, Nobuyoshi Yasuda, Jianguo Yin, Yong-Li Zhong, Joseph Lynch, Teresa Andreani
  • Process for making beta 3 agonists and intermediates
    Patent number: 10087189
    Abstract: The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: October 2, 2018
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: John Y. L. Chung, Kevin Campos, Edward Cleator, Robert F. Dunn, Andrew Gibson, R. Scott Hoerrner, Stephen Keen, Dave Lieberman, Zhuqing Liu, Joseph Lynch, Kevin M. Maloney, Feng Xu, Nobuyoshi Yasuda, Naoki Yoshikawa, Yong-Li Zhong
  • INTERMEDIATES FOR PREPARING CGRP RECEPTOR ANTAGONISTS
    Publication number: 20180127417
    Abstract: The invention encompasses a novel process for making piperidinone carboxamide indane and azainane derivatives, which are CGRP receptor antagonists useful for the treatment of migraine.
    Type: Application
    Filed: December 19, 2017
    Publication date: May 10, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Frank Chen, Carmela Molinaro, W. Peter Wuelfing, Nobuyoshi Yasuda, Jianguo Yin, Yong-Li Zhong, Joseph Lynch
  • PROCESS FOR MAKING BETA 3 AGONISTS AND INTERMEDIATES
    Publication number: 20180065973
    Abstract: The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.
    Type: Application
    Filed: November 9, 2017
    Publication date: March 8, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: John Y.L. CHUNG, Kevin CAMPOS, Edward CLEATOR, Robert F. DUNN, Andrew GIBSON, R. Scott HOERRNER, Stephen KEEN, Dave LIEBERMAN, Zhuqing LIU, Joseph LYNCH, Kevin M. MALONEY, Feng XU, Nobuyoshi YASUDA, Naoki YOSHIKAWA, Yong-Li ZHONG
  • Process for Making Beta 3 Agonists and Intermediates
    Publication number: 20180029981
    Abstract: The present invention is directed to a process for preparing a compound of formula I-11 through multiple-step reactions:
    Type: Application
    Filed: September 26, 2017
    Publication date: February 1, 2018
    Inventors: John Y.L. CHUNG, Kevin CAMPOS, Edward CLEATOR, Robert F. DUNN, Andrew GIBSON, R. Scott HOERRNER, Stephen KEEN, Dave LIEBERMAN, Zhuqing LIU, Joseph LYNCH, Kevin M. MALONEY, Feng XU, Nobuyoshi YASUDA, Naoki YOSHIKAWA, Yong-Li ZHONG
  • Methods and intermediates for preparing macrolactams
    Patent number: 9873707
    Abstract: The present invention includes compounds useful as intermediates in the preparation of macrolactams, methods for preparing the intermediates, and methods for preparing macrolactams. One use of the methods and intermediates described herein is in the production of macrolactam compounds able to inhibit HCV NS3 protease activity. HCV NS3 inhibitory compounds have therapeutic and research applications.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: January 23, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Feng Xu, Richard Desmond, Guy R. Humphrey, Hongming Li, Ji Qi, Rebecca T. Ruck, Zhiguo Jake Song, Tao Wang, Yong-Li Zhong, Jeonghan Park, Laura Marie Artino, Richard John Varsolona